Peer-reviewed veterinary case report
Etoposide slows bone cancer growth in dogs but piroxicam adds no
By Ong, S M et al.·Published in Research in veterinary science·2017·Graduate School of Agricultural and Life Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model.
- Species:
- dog
Plain-English summary
A study looked at a treatment for osteosarcoma, a serious bone cancer, in dogs. Researchers tested a chemotherapy drug called etoposide alone and with another drug, piroxicam, to see how well it could slow down the cancer. The results showed that etoposide alone was effective in delaying tumor growth, while adding piroxicam did not improve the results. This suggests that etoposide could be a promising option for treating osteosarcoma in dogs, but more research is needed to confirm its effectiveness in real-life veterinary settings.
People also search for: dog osteosarcoma treatment · etoposide for dogs cancer · piroxicam and dog tumors
Abstract
Osteosarcoma (OSA) in dogs is locally invasive and highly malignant. Distant metastasis is the most common cause of death. To date, the survival rate in dogs with OSA remains poor. The cytotoxic effects of etoposide against canine OSA cell lines, either alone or in combination with piroxicam, have been previously demonstrated in vitro. The aim of this study was to evaluate the anti-tumour effect of etoposide alone and in combination with piroxicam on canine OSA using murine models. Etoposide single agent treatment significantly delayed tumour progression with a marked reduction in Ki-67 immunoreactivity in tumour tissue. Concomitant treatment with piroxicam did not enhance the anti-tumour efficacy of etoposide. Etoposide single agent treatment and combination treatment with piroxicam down-regulated survivin expression, but was not followed by increased apoptotic activity. These findings indicate that etoposide might be a promising novel therapeutic for canine OSA. Further investigations into its potential for clinical application in veterinary oncology are warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28957780/